Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Kaltura Inc (KLTR) vs BIO-TECHNE Corp (TECH) Price & Performance

Kaltura IncTrade
BIO-TECHNE CorpTrade

Price performance (Past 24H)

Key statistics

Kaltura Inc vs BIO-TECHNE Corp — how do they compare? Kaltura Inc trades at $1.41 (market cap $208.27M), while BIO-TECHNE Corp trades at $71.7 (market cap $11.16B). The key difference: BIO-TECHNE Corp is far larger — about 53.6× Kaltura Inc's market cap, and BIO-TECHNE Corp pays a 0.45% dividend while Kaltura Inc pays none. Which is the better fit depends on your goals.

KLTRTECH
Market Cap
$208.27M$11.16B
Sector
TechnologyHealth
52-Week High
$1.97$72.12
52-Week Low
$1.08$43.31
Enterprise Value
$190.99M$11.24B
Dividend Yield
0.45%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Kaltura Inc

Kaltura (KLTR) trades at $1.385, down 0.36% with a bullish technical signal. The company shows improving fundamentals with three consecutive quarterly EPS beats and revenue stabilizing around $180M. Recent industry recognition includes being named a Leader in virtual event platforms by Forrester and Aragon Research in June 2026. Operating cash flow turned positive in Q1 2026 for the first time in company history, though net margins remain negative at -8.25%.

While technical indicators suggest near-term strength, fundamental challenges persist with negative ROE of -107.84% and high P/B ratio of 44.85. Analyst consensus leans bullish with 44% buy ratings, but profitability concerns and competitive pressures in the digital experience platform space warrant caution. The upcoming Q2 2026 earnings on August 5 will be critical for validating the company's turnaround trajectory.

BIO-TECHNE Corp

Bio-Techne (TECH) trades at $71.64, down 0.67% today, near its 52-week high following Merck KGaA's $73 per share acquisition offer. The stock shows bullish technical signals with strong moving averages, though RSI indicates overbought conditions. Recent earnings have been mixed, with Q4 2025 beating expectations but Q1 2026 missing. The company maintains solid gross margins of 64.96% but faces declining net income margins, down to 6.01% in 2025 from 25.09% in 2023.

The outlook is heavily influenced by the pending acquisition, offering a clear exit near current levels. Risks include shareholder litigation over deal fairness and fundamental profitability pressures. With a high P/E of 103.03, the stock's upside appears capped without the deal, while the $73 bid provides a near-term floor. Investors should weigh acquisition completion probability against operational challenges.

Returns comparison

Trailing returns across standard periods

About Kaltura Inc

Kaltura Inc provides live and on-demand video SaaS solutions to thousands of organizations around the world, engaging hundreds of millions of viewers at home, at work, and school. It also offers specialized industry solutions, including Learning Management System Video, Lecture Capture, and Virtual Classroom for educational institutions, as well as a TV Solution for media and telecom companies. It operates in two reporting segments: (i) Enterprise, Education, and Technology (EE&T)

Read more on KLTR

About BIO-TECHNE Corp

Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.

Read more on TECH